Zhang H Y, Wu Q J, Xie C H, Zhang G
Hubei Cancer Clinical Study Center, Department of Radiochemotherapy, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China.
Exp Ther Med. 2012 Apr;3(4):699-702. doi: 10.3892/etm.2012.455. Epub 2012 Jan 16.
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, and has a poor prognosis. In this study, we reported an exceptional clinical case of primary HCC with metastatic disease in the lungs 1 year following hepatic resection, and in the left adrenal gland 8 years following hepatic resection. Comprehensive treatments, including partial hepatic resection, systemic chemotherapies with various regimens, such as radiotherapy, were administered to this patient. In this case, there was no intrahepatic recurrence of the malignancy and the metastatic disease was sensitive to chemotherapy and radiotherapy. The patient remained alive and in good health for 10 years following the diagnosis of HCC despite early metastatic disease. This indicates that for certain patients with advanced stage HCC, palliative treatments may still be beneficial to their survival. We also discussed the advance in recent research into HCC treatment.
肝细胞癌(HCC)是最常见的肝脏原发性恶性肿瘤,预后较差。在本研究中,我们报告了一例特殊的临床病例,该原发性HCC患者在肝切除术后1年出现肺部转移,在肝切除术后8年出现左肾上腺转移。对该患者实施了综合治疗,包括部分肝切除以及采用多种方案的全身化疗,如放疗。在该病例中,恶性肿瘤未出现肝内复发,转移病灶对化疗和放疗敏感。尽管早期出现转移,但该患者在被诊断为HCC后仍存活且健康状况良好达10年。这表明对于某些晚期HCC患者,姑息治疗可能仍有利于其生存。我们还讨论了HCC治疗的最新研究进展。